Mölnlycke v. MedWay Group: Mepilex Design Patent Dispute Dismissed in 76 Days
Mölnlycke Health Care AB, the Swedish wound care giant behind Mepilex, sued MedWay Group over two design patents protecting the distinctive appearance of its Mepilex foam dressings. The case was filed in the Northern District of Georgia and voluntarily dismissed without prejudice just 76 days later — before MedWay filed any response.
A design patent salvo in wound care — withdrawn before battle
On June 12, 2025, Mölnlycke Health Care AB — the Swedish medical device company and market leader in advanced wound management — filed an infringement action against MedWay Group, Inc. in the U.S. District Court for the Northern District of Georgia. The complaint asserted two design patents, USD737453S and USD743564S, covering the ornamental appearance of Mölnlycke’s Mepilex foam wound dressings. The accused product category was described as a generic alternative to the Mepilex Dressing, suggesting MedWay was marketing or distributing a visually similar substitute.
The case ended on August 27, 2025, when Mölnlycke filed a notice of voluntary dismissal without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). Critically, MedWay had not yet filed an answer to the complaint or any motion for summary judgment, which is precisely the procedural window that permits a plaintiff to dismiss unilaterally as of right — no court order required. The without-prejudice designation means Mölnlycke retains the legal right to refile the same claims against MedWay in the future.
The 76-day duration from filing to dismissal is notably short, and the fact that MedWay had not yet answered suggests the matter may have been resolved through pre-litigation negotiation, a licensing discussion, or a voluntary product withdrawal — though none of that is confirmed in the public record. It is also possible Mölnlycke identified procedural or strategic reasons to withdraw and refile elsewhere. The public docket is silent on any settlement terms, making the true commercial resolution unknown.
Filing to Voluntary dismissal in 76 days
76 days — resolved before defendant answered; well below median district court patent case duration
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): a plaintiff’s unilateral exit right
Federal Rule of Civil Procedure 41(a)(1)(A)(i) allows a plaintiff to dismiss an action without a court order at any time before the defendant serves an answer or a motion for summary judgment. Mölnlycke filed its notice before MedWay responded, triggering this automatic right. No judicial approval was needed, and no merits ruling was made — the case simply ceased to proceed.
No merits decidedPublic record is silent on whether a deal was reached
A without-prejudice dismissal preserves Mölnlycke’s right to refile identical claims against MedWay at a later date. It does not signal a win or loss for either party on the merits. The public docket does not disclose whether this exit was accompanied by a settlement, a licensing agreement, or MedWay ceasing to sell the accused product. The distinction matters: if no deal was struck, the dispute may resurface.
Refiling rights preservedMedWay escapes without prejudice — for now
MedWay Group faces no court judgment, no injunction, and no damages award as a result of this dismissal. However, the without-prejudice nature of the exit means MedWay cannot treat this as a clean slate. If it continues to manufacture or distribute products that Mölnlycke believes infringe USD737453S or USD743564S, a refiled action remains a credible threat. MedWay should assess whether its product design has been modified or whether a licence is in place.
No judgment enteredDesign patent enforcement in wound care remains a live risk
Mölnlycke’s willingness to file — and retain the right to refile — signals that it actively monitors generic alternatives to Mepilex and will use design patent rights as an enforcement tool. For distributors and generic wound care suppliers, this case is a reminder that ornamental design protection extends beyond aesthetics: it can restrict market entry for visually similar foam dressings. FTO clearance on Mepilex-adjacent products is advisable.
Design IP enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Molnlycke Health Care AB | Individual | Swedish advanced wound care company — holder of USD737453S and USD743564SSearch in Eureka ↗ |
| Defendant | MedWay Group, Inc. | Company | MedWay Group, Inc. — U.S. distributor or marketer of generic Mepilex-format dressingsSearch in Eureka ↗ |
| Plaintiff counsel | Devdhi Kasana | Attorney | Counsel for Molnlycke Health Care ABSearch in Eureka ↗ |
| Plaintiff counsel | Jason A. Engel | Attorney | Counsel for Molnlycke Health Care ABSearch in Eureka ↗ |
| Plaintiff counsel | Nolan R. Hubbard | Attorney | Counsel for Molnlycke Health Care ABSearch in Eureka ↗ |
| Plaintiff counsel | Robert James Leonard | Attorney | Counsel for Molnlycke Health Care ABSearch in Eureka ↗ |
| Plaintiff law firm | K&L Gates LLP- Chicago | Law Firm | Representing Molnlycke Health Care ABSearch in Eureka ↗ |
| Plaintiff law firm | Meunier Carlin & Curfman, LLC | Law Firm | Representing Molnlycke Health Care ABSearch in Eureka ↗ |
| Presiding judge | Judge Victoria M. Calvert | Judge | Georgia Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice cites Rule 41(a)(1)(A)(i) and expressly confirms MedWay had not yet answered or moved for summary judgment — the precise procedural prerequisites for a unilateral plaintiff exit. The without-prejudice designation is legally significant: it carries no res judicata effect, leaves both design patents fully enforceable, and preserves Mölnlycke’s ability to refile the same claims. The record contains no merits findings on infringement, invalidity, or claim scope.
USD737453S & USD743564S — Mepilex foam wound dressing ornamental designs
USD737453S and USD743564S are U.S. design patents protecting the ornamental appearance of Mölnlycke’s Mepilex range of foam wound dressings. Design patents protect the way a product looks — not how it functions — and are infringed when an ordinary observer would find the accused product substantially similar in overall visual impression. The application numbers US29/469592 and US29/451682 place these in Mölnlycke’s sustained design registration programme for Mepilex, covering successive or variant dressing configurations in the same product family.
Mepilex is among the most commercially significant advanced wound care dressing lines globally, with Mölnlycke holding strong market positions in foam-based wound management. Design patent protection on a market-leading product creates a meaningful barrier for generic entrants: even if the silicone or foam formulation is off-patent, a visually similar dressing can infringe a design registration. This dual protection strategy — utility and design — is increasingly common among wound care originators seeking to extend commercial exclusivity in the face of generic competition.
Should you run an FTO against USD737453S and USD743564S?
If your company manufactures, distributes, or private-labels foam wound dressings that resemble the Mepilex format — particularly border foam or silicone-backed designs — both USD737453S and USD743564S warrant FTO clearance before U.S. market entry. This case establishes that Mölnlycke monitors and litigates against generic Mepilex alternatives. The without-prejudice dismissal does not indicate these patents are weak; it may simply reflect an off-docket resolution with MedWay specifically.
PatSnap Eureka’s FTO Search Agent can map USD737453S and USD743564S against your product’s ornamental design features, surface the full Mölnlycke design patent family, and flag related pending applications that may issue. For wound care product teams and IP counsel evaluating foam dressing SKUs, Eureka can accelerate the design clearance process and identify design-around opportunities before commercialisation.
Run a freedom-to-operate analysis on USD737453S to assess your product’s exposure
Run FTO in Eureka →Similar design patent cases in advanced wound care and medical devices
Explore related design patent infringement actions in wound care and medical device markets filed in U.S. district courts, including the Northern District of Georgia.
What this case signals for the wound care IP landscape
Mölnlycke’s design patent strategy against generic Mepilex alternatives has broader implications for wound care suppliers and distributors entering this market segment.
Design patents are a real barrier in wound care generics
This case confirms Mölnlycke treats its Mepilex design patents as enforceable market-exclusion tools, not just registration formalities. Companies commercialising foam wound dressings that resemble Mepilex in ornamental appearance face a credible litigation risk — even if the underlying utility is off-patent.
A 76-day dismissal without an answer typically signals off-docket resolution
When a plaintiff voluntarily dismisses before the defendant even answers, it commonly suggests a negotiated resolution — a licence, a product recall, or a design-around commitment. None of this is confirmed here, but the pattern is consistent with a pre-answer commercial agreement reached privately.
AB v MedWay — key questions answered
Mölnlycke Health Care AB asserted two U.S. design patents: USD737453S (application US29/469592) and USD743564S (application US29/451682). Both protect the ornamental appearance of its Mepilex foam wound dressings. The accused product was described as a generic alternative to the Mepilex Dressing.
Mölnlycke filed a voluntary notice of dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i) before MedWay answered or filed a motion for summary judgment. Dismissed without prejudice means no merits were decided and Mölnlycke retains the right to refile the same claims in the future. The public record does not disclose the reason for the withdrawal.
Yes. A without-prejudice dismissal carries no res judicata effect, so Mölnlycke is legally free to refile claims based on USD737453S and USD743564S against MedWay in any competent U.S. jurisdiction. The prior filing also constitutes formal notice of the patents to MedWay, which is relevant if enhanced damages were later sought in a refiled action.
USD737453S and USD743564S are U.S. design patents covering the ornamental appearance — the visual design — of Mölnlycke’s Mepilex foam wound dressings. Design patents protect how a product looks, not how it works. Infringement is assessed using the ordinary observer test: whether an ordinary purchaser would find the accused product substantially similar in overall visual impression to the patented design.
The case (1:25-cv-03303) was filed in the U.S. District Court for the Northern District of Georgia and assigned to Judge Victoria M. Calvert. The case closed on August 27, 2025, after just 76 days, following Mölnlycke’s voluntary dismissal notice before MedWay filed any responsive pleading.
PatSnap Eureka searches patents and litigation data to answer instantly.